Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiol Young ; 29(1): 1-10, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30375310

ABSTRACT

A bicuspid aortic valve is not only a common congenital heart defect but also an enigmatic condition that can cause a large spectrum of diseases, such as aortic valve stenosis and severe heart failure in newborns whereas aortic dissection in adults. On the contrary, a bicuspid aortic valve can also occur with normal function throughout life and never need treatment. Numerous genetic mechanisms are involved in the abnormal cellular functions that may cause abnormal development of the aortic valve during early foetal life. As several chromosomal disorders are also associated with a bicuspid valve, there does not appear to be an apparent common trigger to the abnormal development of the aortic valve. The clinical care of the bicuspid aortic valve patient has been changed by a significant body of evidence that has improved the understanding of the natural history of the disease, including when to best intervene with valve replacement and when to provide prophylactic aortic root surgery. Moreover, as bicuspid valve disease is also part of various syndromes, we can identify high-risk patients in whom a bicuspid valve is much more unfavourable than in the normal population. This review provides an overview of all aspects of the bicuspid aortic valve condition and gives an updated perspective on issues from pathophysiology to clinical care of bicuspid aortic valve disease and associated aortic disease in asymptomatic, symptomatic, and pregnant patients, as well as our viewpoint on population screening.


Subject(s)
Aortic Valve/abnormalities , Aortic Valve/physiopathology , Heart Defects, Congenital/complications , Heart Valve Diseases/genetics , Mitral Valve/physiopathology , Aortic Dissection/etiology , Aortic Valve/pathology , Heart Defects, Congenital/pathology , Heart Valve Diseases/physiopathology , Heart Valve Prosthesis Implantation , Humans , Mitral Valve/pathology
2.
Ann Vasc Surg ; 48: 252.e5-252.e8, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29421423

ABSTRACT

Abdominal aortic aneurysms (AAAs) are very rare in Marfan syndrome. We present a case with a young nonsmoking and normotensive male with Marfan syndrome, who developed an infrarenal AAA that presented with rupture to the retroperitoneal cavity causing life-threatening bleeding shock. The patient had acute aortic surgery and survived. Five months before this incident, the patient had uneventful elective aortic root replacement (ad modum David) due to an enlarged aortic root. At that time, his abdominal aorta was assessed with a routine ultrasound scan that showed a normal-sized abdominal aorta. This documents that the aneurysm had evolved very rapidly despite young age and absence of risk factors.


Subject(s)
Aortic Aneurysm, Abdominal/etiology , Aortic Rupture/etiology , Marfan Syndrome/complications , Aortic Aneurysm, Abdominal/diagnostic imaging , Aortic Aneurysm, Abdominal/surgery , Aortic Rupture/diagnostic imaging , Aortic Rupture/surgery , Aortography/methods , Biopsy , Blood Vessel Prosthesis Implantation , Computed Tomography Angiography , Humans , Male , Marfan Syndrome/diagnosis , Treatment Outcome , Ultrasonography , Young Adult
3.
Eur J Nutr ; 48(1): 1-5, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19030909

ABSTRACT

BACKGROUND: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an emerging independent risk factor for cardiovascular disease (CVD). Lp-PLA(2) can be modified by lipid lowering drugs, but it is unknown whether diet can reduce plasma levels of Lp-PLA(2). AIM OF THE STUDY: The aim of the trial was to study the effect of marine n-3 polyunsaturated fatty acids (PUFA) on plasma Lp-PLA(2) levels in healthy subjects. METHODS: Sixty healthy subjects were randomized to a moderate dose (2 g) of n-3 PUFA, a high dose (6.6 g) of n-3 PUFA or olive oil (control) daily for 12 weeks. Plasma Lp-PLA(2) was measured at baseline and after the interventions. RESULTS: Plasma Lp-PLA(2) levels were unchanged in all three groups before and after the supplements. Neither did the results differ between groups. There was no correlation between the content of n-3 PUFA in platelets or granulocytes or plasma Lp-PLA(2). CONCLUSION: Marine n-3 PUFA had no effect on plasma levels of Lp-PLA(2) in healthy adults and relatively young people.


Subject(s)
1-Alkyl-2-acetylglycerophosphocholine Esterase/blood , Fatty Acids, Omega-3/administration & dosage , Fish Oils/administration & dosage , Adult , Blood Platelets/chemistry , Body Mass Index , Cholesterol , Cholesterol, LDL/blood , Dietary Supplements , Docosahexaenoic Acids/blood , Eicosapentaenoic Acid/blood , Female , Granulocytes/chemistry , Humans , Male , Middle Aged , Olive Oil , Plant Oils/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...